Here’s a look at four changes in the second round of healthcare bill revisions that just weren’t enough to muster up enough votes.
The Republican Senate’s first attempt to revise its proposed healthcare bill, the Better Care Reconciliation Act (BCRA) of 2017-which would replace the Affordable Care Act (ACA), didn’t have enough support to proceed to a vote. GOP Senators made more revisions and presented them on July 13. But within a few days, four GOP Senators announced that they would not vote for the revised bill, causing it to fail yet again.
Here’s a look at four changes in the second round of revisions that just weren’t enough to muster up enough votes.
Says Hoff, “This is a nod to conservative Republicans because the more affluent are likely the ones who would benefit most as poorer citizens often have little additional income to put into these accounts to begin with, and the pre-tax savings accrues most to those in higher income tax brackets. Many have labeled it as just another tax shelter for wealthy Americans.”
“With the exception of the Cruz Amendment, which would represent a significant change to the status quo and to previous House and Senate proposals, many of the changes in the most recent draft seemed more political than policy-driven,” Fitzgerald concludes. “Senate leadership was seeking votes from previous holdouts, including Senators Cruz and Mike Lee, and also from moderate Senators who were concerned about opiates or the optics of a large tax cut for higher-income taxpayers at the same time Medicaid was cut.”
Karen Appold is a medical writer in Lehigh Valley, Pennsylvania.
Extending the Capabilities of the EHR Through Automation
August 2nd 2023Welcome back to another episode of "Tuning In to the C-Suite," where Briana Contreras, an editor of Managed Healthcare Executive, had the pleasure of chatting with Cindy Gaines, chief clinical transformation officer at Lumeon.
Listen
Updated: FDA Committee, Concerned about Bias, Votes No on Psychedelic in PTSD
June 5th 2024Patients with PTSD in the clinical trials of midomafetamine were able to guess whether they received treatment or placebo. Regulators and advisory committee members said this could have impacted efficacy results. FDA’s decision is expected by Aug. 11, 2024.
Read More